CT-1530 is under clinical development by Centaurus Biopharma and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase II drugs for Mantle Cell Lymphoma have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CT-1530’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CT-1530 is under development for the treatment of relapsed or refractory B cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, Waldenstrom’s macroglobulinemia, diffuse large B-cell lymphoma, small cell lymphocytic leukemia, mantle cell lymphoma and follicular lymphoma. The drug candidate acts by targeting Burton’s tyrosine kinase. It is in Phase II stage of development for mantle cell lymphoma.
For a complete picture of CT-1530’s drug-specific PTSR and LoA scores, buy the report here.